As of May 02
| +0.06 / +0.80%|
The 7 analysts offering 12-month price forecasts for Amicus Therapeutics Inc have a median target of 15.00, with a high estimate of 17.00 and a low estimate of 9.00. The median estimate represents a +99.20% increase from the last price of 7.53.
The current consensus among 7 polled investment analysts is to Buy stock in Amicus Therapeutics Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.